Chemotherapy is meant to be toxic, but it is particularly aimed at the tumor cells. Collateral damage may occur to normal cells and tissues, especially if they are fairly rapidly regenerating, as is the case for bone marrow cells, intestinal epithelial cells, and liver cells after hepatic injury. The liver has a great capacity to resist injury, overcome it, and to regenerate, even after quite massive injury (resection of 50%—65%, for example). This capacity may make it susceptible to chemotherapeutic toxicity, and a struggle between injury and adaptation, leading to recovery and tolerance or to failure and death. If the chemotherapy is aimed just at delaying progression of the cancer for a few weeks or months, it may not be worth the risk of irreversible liver injury developing in that time. Close clinical observation and sound clinical judgment are required.
Alberg, A.J., Park, J.W., Hager, B.W., Brock, M.V., and Diener-West, M. ( 2004). The use of ‘‘overall accuracy’’ to evaluate validity of screening or diagnostic tests. J Gen Int Med19, 460-65.
2.
Alden, C., Lin, J., and Smith, P. ( 2003). Predictive toxicology technology for avoiding idiosyncratic liver injury. Preclinica2, 27-35.
3.
Assis, D.N., and Navarro, V.J. ( 2009). Human drug hepatotoxicity: A contemporary clinical perspective . Expert Opin Drug Metab Toxicol5, 463-73.
4.
Atiqi, R., van Iersel, C., and Cleophas, T.J. ( 2009). Accuracy assessments of quantitative diagnostic tests for clinical research. Int J Clin Pharmacol Ther47, 153-58.
5.
Blumgart, L.H., Leach, K.G., and Karran, S.J. ( 1971). Observations on liver regeneration after right hepatic lobectomy. Gut12, 922-28.
6.
Chun, Y.S., Laurent, A., Maru, D., and Vautney, J-N. ( 2009). Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol10, 278-86.
7.
Cleophas, T.J., Droogendijk, J., and van Ouwerkerk, B.M. (2008). Validating diagnostic tests, correct and incorrect methods, new developments. Curr Clin Prarmacol3, 70-76.
8.
Córdoba, J., O’Riordan, K., Dupuis, J., Borensztajn, J., and Blei, A.T. ( 1998). Diurnal variation of serum alanine transaminase activity in chronic liver disease. (Letter)Hepatology28, 1724-25.
9.
Davidson, C. S., Leevy, C. M., and Chamberlayne, E. C. (eds.) (1979). Guidelines for Detection of Hepatotoxicity due to Drugs and Chemicals. [Fogarty Conference, 1978] NIH Publication No. 79-313. US Government Printing Office, Washington, DC, p. 109.
10.
Eklund, J.W., Trifilio, S., and Mulcahy, M.F. ( 2005). Chemotherapy dosing in the setting of liver dysfunction . Oncology (Williston Park) 19, 1057-63.
11.
Field, K.M., Dow, C., and Michael, M. ( 2008). Part I: Liver function in oncology: Biochemistry and beyond. Lancet Oncol9, 1092-101.
12.
Field, K.M., and Michael, M. ( 2008). Part II: Liver function in oncology: Toward safer chemotherapy use. Lancet Oncol9, 1181-90.
13.
Floyd, J., Mirza, I., Sachs, B., and Perry, M.C. ( 2006). Hepatotoxicity of chemotherapy. Semin Oncol33, 50-67.
14.
Fontana, R.J., Watkins, P.B., Bonkovsky, H.L., Chalasani, N., Davern, T., Serrano, J., and Rochon, J., for the DILIN Study Group. ( 2009). Drug-induced liver injury network (DILIN) prospective study: Rationale, design, and conduct. Drug Safety32, 55-68.
15.
Graham, D.J., Green, L., Senior, J.R., and Nourjah, P. ( 2003). Troglitazoneinduced liver failure: A case study . Am J Med114, 299-306.
16.
Kaplan, M.M. ( 2002). Alanine aminotransferase levels: What’s normal ? Ann Intern Med137, 49-51.
17.
Karmen, A., Wroblewski, F., and LaDue, J.S. ( 1955). Transaminase activity in human blood. J Clin Invest34, 126-31.
18.
King, P.D., and Perry, M.C. ( 1995). Hepatotoxicity of chemotherapeutic and oncologic agents . Gastroenterol Clin North Am24, 969-90.
19.
Kopanoff, D.E., Snider, D.E. Jr., and Caras, G.J. ( 1978). Isoniazid-related hepatitis: A U.S. Public Health Service cooperative surveillance study. Am Rev Resp Dis117, 991-1001.
20.
Lawrence, T.S., Robertson, J.M., Anscher, M.S., Jirtle, R.L., Ensminger, W.D., and Fajardo, L.F. ( 1995). Hepatic toxicity resulting from cancer treatment . Int J Radiat Oncol Biol Phys31, 1237-48.
21.
Ledley, R.S., and Lusted, L.B. ( 1959). Reasoning foundations of medical diagnosis: Symbolic logic, probability, and value theory aid our understanding of how physicians reason. Science130, 9-21.
22.
National Cancer Institute.Common Toxicity Criteria for Adverse Events (CTCAE), version 3.0 (2007). Available at: https://webapps.ctep.nci.nih.gov/webobjs/ctc/webhelp/welcome_to_ctcae.htm . Accessed 13 October 2009.
23.
Nolan, C.M., Goldberg, S.V., and Buskin, S.E. ( 1999). Hepatotoxicity associated with isoniazid preventative therapy: A 7-year survey from a public health tuberculosis clinic. JAMA281, 1014-18.
24.
Prado, C.M.M., Baracos, V.E., McCargar, L.J., Mourtzakis, M., Mulder, K.E., Reiman, T., Butts, C.A., Scarfe, A.G., and Sawyer, M.B. ( 2007). Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res13, 3264-68.
25.
Prati, D., Taioli, E., Zanella, A., Della Torre, E., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., Conte, D., Colombo, M., and Sirchia, G. ( 2002). Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med137, 1-10.
26.
Senior, J.R. ( 1999). Drugs and the Liver: What They Do To Each Other . (FDA conference held in at University of Maryland Shady Grove Center ). Available at http://www.fda.gov/downloads/ScienceResearch/ResearchAreas/ucm072996.pdf. Accessed 13 October 2009.
27.
Senior, J.R. ( 2003). Healthy ranges for alanine aminotransferase levels . Ann Intern Med138, 156-57.
28.
Senior, J.R., and Avigan, M.I. ( 2008). Classification system for likelihood and severity of drug-induced liver injury to score clinical importance of the case. (Abstract #445 and poster, AASLD annual meeting, San Francisco CA, 1 Nov 2008)Hepatology48, 506A-507A.
29.
Temple, R. ( 2006). Hy’s law: Predicting serious hepatotoxicity . Pharmacoepidemiol Drug Saf15, 241-43.
